Circle Pharma Receives FDA Orphan Drug Designation for CID-078 for the Treatment of Small Cell Lung Cancer
'The Orphan Drug Designation from the FDA underscores both the seriousness of small cell lung cancer and the lack of effective treatment options,' said Michael C. Cox, PharmD, MHSc, BCOP, SVP, and head of early development Circle Pharma.
Small-cell lung cancer is a highly aggressive form of lung cancer that accounts for approximately 13–15% of all lung cancer cases 1 and is strongly linked to tobacco exposure. Despite existing treatments, SCLC has a high recurrence rate and is associated with poor overall prognosis. While improvements in overall survival are occurring with newer therapies, most patients experience rapid disease progression 2.
'The Orphan Drug Designation from the FDA underscores both the seriousness of small cell lung cancer and the lack of effective treatment options,' said Michael C. Cox, PharmD, MHSc, BCOP, SVP, and head of early development Circle Pharma. 'We are committed to accelerating the clinical development of CID-078 to offer new hope for patients who face limited therapeutic choices.'
The FDA's Orphan Drug Designation program is intended to promote the development of drugs for rare diseases or conditions affecting fewer than 200,000 people in the United States 3. This designation provides several development incentives, including seven years of market exclusivity upon regulatory approval, tax credits for qualified clinical trial costs, and eligibility to apply for FDA-administered research grants 4.
Circle Pharma has initiated a Phase 1 clinical trial (NCT06577987) of CID-078 to evaluate its safety, tolerability, pharmacokinetics, and early signs of anti-tumor activity in patients with advanced solid tumors, including SCLC.
About CID-078, Circle Pharma's Cyclin A/B RxL Inhibitor Program
CID-078 is an orally bioavailable macrocycle with dual cyclin A and B RxL inhibitory activity that selectively targets tumor cells with oncogenic alterations that cause cell cycle dysregulation. In biochemical and cellular studies, Circle Pharma's cyclin A/B RxL inhibitors have been shown to potently and selectively disrupt the protein-to-protein interaction between cyclins A and B and their key substrates and modulators, including E2F (a substrate of cyclin A) and Myt1 (a modulator of cyclin B). Preclinical studies have demonstrated the ability of these cyclin A/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models. A multi-center phase 1 clinical trial (NCT06577987) is currently enrolling patients.
About Circle Pharma, Inc.
South San Francisco-based Circle Pharma is a clinical-stage biopharmaceutical company harnessing the power of macrocycles to develop therapies for cancer and other serious illnesses. The company's proprietary MXMO™ platform overcomes key challenges in macrocycle drug development, enabling the creation of intrinsically cell-permeable and orally bioavailable therapies for historically undruggable targets. Circle Pharma's pipeline is focused on targeting cyclins, key regulators of the cell cycle that drive many cancers. Its lead program, CID-078, a cyclin A/B-RxL inhibitor, is in a Phase 1 clinical trial (NCT06577987) for patients with advanced solid tumors.
To learn more about Circle Pharma, please visit www.circlepharma.com.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
JoAcademy Partners With Truecaller to Deliver Trusted, Contextual Communication Experience for the Student Ecosystem in Jordan
BUSINESS WIRE)-- JoAcademy, Jordan's leading e-learning platform, has joined hands with Truecaller, the leading global communications platform to enhance how it connects with its student community. The collaboration focuses on strengthening trust and clarity in customer communication by integrating Truecaller Customer Experience Solution. In a digital learning environment, seamless and credible communication is essential. JoAcademy is now using Truecaller Customer Experience Solution to ensure that students, parents, and users instantly recognize when the call is coming from the official JoAcademy team. With the business name displayed in Arabic and verified branding, confusion and hesitation around unknown numbers are eliminated. Beyond verification, JoAcademy has enabled the Call Reason capability with localisation in Arabic, allowing the team to communicate the purpose of the call upfront. Whether it's a course recommendation, a payment reminder, or a quick check-in from support, users now know exactly why they're being contacted, bringing clarity and reducing friction. In addition, JoAcademy is using other capabilities from the Truecaller Customer Experience suite to enhance its communication further. With Video Caller ID, each call is visually branded, making interactions more engaging and instantly recognizable. The Call Me Back capability empowers students to respond at their convenience in case they miss a call and suggest the time slot they want to get a call back. Additionally, the User Feedback capability allows JoAcademy to gather real-time input from users, helping the team continuously refine and improve the overall service experience. Commenting on the partnership, Alaa Jarrar, CEO at Jo Academy, said: "At JoAcademy, students are at the heart of everything we do. Trust and clarity in communication are essential pillars of a successful learning experience. Our partnership with Truecaller for Business reflects this commitment, allowing us to connect with students and parents in a more effective and transparent way. This step aligns with our vision for the future of digital education in Jordan, where every interaction is an opportunity to build stronger, more trusted relationships within our learning community." Priyam Bose, Global Head of GTM and Developer Products at Truecaller, added: "JoAcademy represents a new wave of digital-first education brands in Jordan, reimagining the student communication experience. By combining Business identity, localised context, and customer experience capabilities such as video caller ID and call me back, they're turning everyday conversations into opportunities that empower richer, more engaging communication. This association reflects a deep commitment to student experience and brand integrity. We're proud to support their mission to help set a new standard for student-first engagement in the region." Truecaller Customer Experience Solution is used by over 2,500+ businesses globally across industries to bring trust, identity, and efficiency to business communication. With this partnership, JoAcademy joins a growing network of organizations putting customer experience and verified engagement at the center of their communication strategy.
Newsweek
4 hours ago
- Newsweek
FDA Issues Risk Warning After Mushrooms Recalled Nationwide
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. The U.S. Food and Drug Administration (FDA) has issued a national advisory and classified a recent mushroom recall as Class I, the agency's highest level risk designation, due to potential Listeria monocytogenes contamination. Newsweek contacted Hofood99 Inc via telephone for comment outside of usual working hours on Sunday and left a voicemail message. Why It Matters The Class I recall status indicates that the product poses a risk of causing serious health consequences or death if consumed. Listeria monocytogenes can lead to severe and sometimes fatal infections, especially during pregnancy, and for newborns, elderly adults, and people with weakened immune systems. Although no illnesses have been reported, the risk to public health is significant, prompting the warnings from the FDA. This incident highlights ongoing concerns surrounding food safety, especially in the distribution and handling of perishable produce. What to Know As reported by Newsweek, the firm-initiated recall affects enoki mushrooms distributed by Hofood99 Inc, located at 21903 56th Avenue Oakland Gardens, New York, 11364. The affected mushrooms were sold in 200‑gram green plastic bags and marked with UPC 6 976532 310051 on the back label; a picture of enoki mushrooms is outlined in green on the front of the package. The recall number is H-0261-2025. Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) Recalled packages of Enoki Mushroom from Hofood99 Inc. can be seen in a June 11, 2025, recall alert. (Photo from the U.S. Food and Drug Administration) The 90 boxes of affected product were shipped to retailers nationwide and tested positive for Listeria during routine sampling conducted by the Michigan Department of Agriculture. Consumers are advised not to eat the product and to either discard it or return it to the store where it was purchased for a full refund. Symptoms of Listeria infection may include high fever, muscle aches, nausea, diarrhoea, and in severe cases, complications such as meningitis or miscarriage. Consumers are advised to clean and sanitise refrigerators and any surfaces that may have come into contact with the recalled mushrooms, as the bacteria can survive and spread in cold environments. What People Are Saying The FDA in the original alert in part: "The contamination was discovered after samples were collected from a store in Michigan and subsequent analysis by Michigan Department of Agriculture & Rural Development (MDARD) Laboratory Division revealed the presence of Listeria monocytogenes." The FDA, as stated on its website: "A recall is a method of removing or correcting products that are in violation of laws administered by the Food and Drug Administration (FDA). Recall is a voluntary action that takes place because manufacturers and distributors carry out their responsibility to protect the public health and well-being from products that present a risk of injury or gross deception or are otherwise defective. What Happens Next Consumers with questions can contact Hofood99 Inc. at (917) 756‑9833 during business hours of 9:00 a.m. to 2:00 p.m., Monday to Friday. Further updates are available on the FDA's website. Additional information on recalls can be found via the FDA's Recalls, Market Withdrawals, & Safety Alerts.
Yahoo
6 hours ago
- Yahoo
Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target
Atai Life Sciences N.V. (NASDAQ:ATAI) is among the . Aegis Capital analysts have reaffirmed their Buy rating on Atai Life Sciences N.V. (NASDAQ:ATAI), with an unchanged price target of $8.00, following the favorable Phase 2b results of the BPL-003 treatment for the company's Treatment Resistant Depression (TRD). Around 193 depression patients, who didn't respond to previous treatment, were part of the Phase 2b trial testing three doses: 0.3 mg, 8 mg, and 12 mg. Not only the 8mg but also the 12mg dose showcased statistically significant improvement in an FDA-accepted measurement of depression, with a healthy side-effect profile. A close-up of a medical professional providing advice to a patient struggling with opioid use disorder. The research firm believes these robust results strengthen the company's efforts to proceed to a Phase 3 clinical program, which would result in marketing approval. Going forward, Atai Life Sciences N.V. (NASDAQ:ATAI) plans to schedule a post-Phase 2 meeting with the FDA, with the Phase 3 trial expected to begin only at the end of the upcoming year. Another noteworthy development is the company's recent $50 million private capital raise, which involved the sale of 18,264,840 common shares with 25% warrant coverage at the market price. Moves like these highlight Atai Life Sciences N.V. (NASDAQ:ATAI)'s capacity to raise cash when needed. Atai Life Sciences N.V. (NASDAQ:ATAI) is a German clinical-stage biopharmaceutical company that researches, develops, and markets mental health treatments in the United States, Germany, and Canada. With a market capitalization of $587.639 million, the company is committed to healing mental health disorders. While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None.
